

## Consolidated Financial Results for the Third Quarter of the Year Ending December 31, 2024

[Japanese GAAP]

November 8, 2024

Company name: Carna Biosciences, Inc. Stock Exchange listing: Tokyo Stock Exchange (Growth)  
 Stock code: 4572 URL: <https://www.carnabio.com/english/>  
 Representative: Kohichiro Yoshino, President and CEO  
 Contact: Emi Yamamoto, Director, Business Administration Division TEL: +81-78-302-7075  
 Scheduled date of dividend payment: —  
 Supplementary materials for financial results: Yes  
 Financial results briefing: —

(Rounded down to the nearest million yen)

### 1. Consolidated Financial Results for the Nine Months Ended September 30, 2024

(1) Consolidated operating results (Percentages show changes from the same period of the previous fiscal year)

	Net sales		Operating profit		Ordinary profit		Profit attributable to owners of parent	
	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%
Nine months ended September 30, 2024	487	(31.5)	(1,578)	—	(1,579)	—	(1,588)	—
Nine months ended September 30, 2023	711	(35.1)	(1,201)	—	(1,203)	—	(1,230)	—

Note: Comprehensive income Nine months ended September 30, 2024: (1,587) million yen (—%)

Nine months ended September 30, 2023: (1,196) million yen (—%)

	Basic earnings per share		Diluted earnings per share	
	Yen		Yen	
Nine months ended September 30, 2024	(90.52)		—	
Nine months ended September 30, 2023	(73.74)		—	

### (2) Consolidated financial position

	Total assets	Net assets	Equity-to-asset ratio
	Millions of yen	Millions of yen	%
As of September 30, 2024	2,977	2,654	89.1
As of December 31, 2023	4,349	3,877	89.1

Reference: Shareholders' equity As of September 30, 2024: 2,654 million yen As of Dec. 31, 2023: 3,877 million yen

### 2. Dividends

	Dividend per share				
	End of 1 <sup>st</sup> quarter	End of 2 <sup>nd</sup> quarter	End of 3 <sup>rd</sup> quarter	Year-end	Total
	Yen	Yen	Yen	Yen	Yen
FY2023	—	0.00	—	0.00	0.00
FY2024	—	0.00	—	—	—
FY2024 (Forecast)	—	—	—	0.00	0.00

Note: Revision to the most recently announced dividend forecast: None

### 3. Consolidated Financial Forecast for FY2024 (January 1, 2024 to December 31, 2024)

(Percentages show changes from the same period of the previous fiscal year)

	Net sales		Operating income		Ordinary income		Profit attributable to owners of parent		Earnings per share
	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%	Yen
FY2024	925	(43.0)	(2,201)	—	(2,208)	—	(2,225)	—	(129.81)

Note: Revision to the most recently announced financial forecast: None

**\* Notes**

(1) Changes in significant subsidiaries during the period (changes in specified subsidiaries resulting in the change in the scope of consolidation): None

(2) Application of special accounting methods for presenting quarterly consolidated financial statements: None

(3) Changes in accounting policies, accounting estimates, and restatements

1) Changes in accounting policies due to revisions in accounting standards, etc.: None

2) Changes in accounting policies other than 1) above: None

3) Changes in accounting estimates: None

4) Restatements: None

(4) Number of shares outstanding (common stock)

1) Number of shares outstanding at the end of the period (including treasury stock)

As of September 30, 2024: 18,056,900 shares      As of Dec. 31, 2023: 17,151,900 shares

2) Number of treasury stock at the end of the period

As of September 30, 2024: 11,124 shares      As of Dec. 31, 2023: 7,124 shares

3) Average number of shares outstanding during the period

Third quarter of FY2024: 17,549,758 shares      Third quarter of FY2023: 16,683,924 shares

\* This financial report is exempt from quarterly review procedures by auditors.

\* Note to ensure appropriate use of forecasts and other remarks

The forecasts and other forward-looking statements included in this document are based on the information currently available to the management and certain assumptions considered by the management to be reasonable. Actual operating results may differ materially from these statements for various factors.

## Contents

Consolidated Financial Statements.....	2
(1) Consolidated Balance Sheet.....	2
(2) Consolidated Statements of Income and Comprehensive Income .....	4

**Consolidated Financial Statements****(1) Consolidated Balance Sheet**

	(Thousands of yen)	
	FY2023	FY2024
	(As of Dec. 31, 2023)	(As of Sep. 30, 2024)
<b>Assets</b>		
Current assets		
Cash and deposits	2,889,101	2,281,597
Accounts receivable–trade	788,195	76,328
Merchandise and finished goods	94,383	103,906
Work in process	12,390	11,162
Raw materials and supplies	33,367	38,459
Other	374,044	334,596
Total current assets	4,191,484	2,846,051
Non-current assets		
Property, plant and equipment	105,498	93,110
Intangible assets	1,091	474
Investments and other assets	51,817	37,783
Total non-current assets	158,407	131,368
Total assets	4,349,891	2,977,419

	(Thousands of yen)	
	FY2023	FY2024
	(As of Dec. 31, 2023)	(As of Sep. 30, 2024)
Liabilities		
Current liabilities		
Accounts payable—trade	1,200	—
Current portion of long-term borrowings	120,000	45,003
Accounts payable-other	190,098	163,684
Income taxes payable	28,273	16,207
Other	36,349	17,507
Total current liabilities	375,921	242,403
Non-current liabilities		
Long-term borrowings	28,402	13,408
Asset retirement obligations	38,657	39,129
Other	29,375	28,186
Total non-current liabilities	96,435	80,724
Total liabilities	472,356	323,127
Net assets		
Shareholders' equity		
Capital stock	2,076,474	2,258,599
Capital surplus	5,827,683	6,009,808
Retained earnings	(4,075,386)	(5,663,971)
Treasury shares	(222)	(222)
Total shareholders' equity	3,828,549	2,604,213
Accumulated other comprehensive income		
Valuation difference on available-for-sale securities	(2,722)	(2,977)
Deferred gains or losses on hedges	—	(1,023)
Foreign currency translation adjustment	51,709	54,080
Total accumulated other comprehensive income	48,986	50,079
Total net assets	3,877,535	2,654,292
Total liabilities and net assets	4,349,891	2,977,419

**(2) Consolidated Statements of Income and Comprehensive Income**  
**Consolidated Statement of Income**

	(Thousands of yen)	
	First nine months of FY2023 (Jan. 1 - Sep. 30, 2023)	First nine months of FY2024 (Jan. 1 - Sep. 30, 2024)
Net sales	711,294	487,218
Cost of sales	123,644	123,167
Gross profit	587,650	364,051
Selling, general and administrative expenses	1,789,406	1,942,060
Operating loss	(1,201,755)	(1,578,009)
Non-operating income		
Interest income	145	13,411
Dividend income	318	330
Foreign exchange gains	6,013	8,492
Other	127	2,423
Total non-operating income	6,605	24,657
Non-operating expenses		
Interest expenses	2,387	2,400
Guarantee commission	577	297
Share issuance costs	5,219	23,109
Other	0	—
Total non-operating expenses	8,185	25,807
Ordinary loss	(1,203,335)	(1,579,158)
Extraordinary losses		
Impairment loss	4,562	5,539
Total extraordinary losses	4,562	5,539
Loss before income taxes	(1,207,898)	(1,584,698)
Income taxes-current	22,530	3,965
Income taxes-deferred	(84)	(78)
Total income taxes	22,445	3,886
Loss	(1,230,344)	(1,588,585)
Loss attributable to owners of parent	(1,230,344)	(1,588,585)

**Consolidated Statement of Comprehensive Income**

	(Thousands of yen)	
	First nine months of FY2023 (Jan. 1 – Sep. 30, 2023)	First nine months of FY2024 (Jan. 1 – Sep. 30, 2024)
Loss	(1,230,344)	(1,588,585)
Other comprehensive income		
Valuation difference on available-for-sale securities	(651)	(254)
Deferred gains or losses on hedges	(615)	(1,023)
Foreign currency translation adjustment	35,318	2,370
Other comprehensive income	34,051	1,092
Comprehensive income	(1,196,293)	(1,587,492)
Comprehensive income attributable to owners of parent	(1,196,293)	(1,587,492)
Comprehensive income attributable to non-controlling interests	—	—

*This financial report is solely a translation of “Kessan Tanshin” (in Japanese, including attachments), which has been prepared in accordance with accounting principles and practices generally accepted in Japan, for the convenience of readers who prefer an English translation.*